Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

about

Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY Host immunity to Cryptococcus neoformans Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa CRL4 complex regulates mammalian oocyte survival and reprogramming by activation of TET proteins Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia Cryptococcal meningitis: epidemiology and therapeutic options.Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016.Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda.Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100.Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania Molecular and nonmolecular diagnostic methods for invasive fungal infections.Cost-effective diagnostic checklists for meningitis in resource-limited settings.Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012.A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions Methods of rapid diagnosis for the etiology of meningitis in adults High prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia.Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYA.Immune reconstitution inflammatory syndrome in HIV-infected patients Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.Cryptococcosis diagnosis and treatment: What do we know now Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.Treatment principles for Candida and Cryptococcus.Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

P2860

Q21144604-07EF0D62-F708-45DA-A484-9F387A7A853B Q24610164-BECCF9E4-EE1B-4B55-8817-81C56A21B33E Q24610933-EE92506C-F767-4B0E-82EC-65732897B414 Q24620256-76D17923-D9EA-41E1-B048-042519F950DC Q26746020-C4CC5880-53A8-4E07-8598-6C694EB04B28 Q26783210-831EAF81-6BC5-42CD-9BC1-F94EC3D2085F Q26823438-1E361A6C-B7B7-4FB6-A7C6-F96A17659E80 Q26994750-B31C02B7-8D6F-44F9-864B-CA9B43A0D660 Q28078958-9C0AA360-A5DF-4389-8582-526609DDEC5A Q28534733-D84EEBF2-7BDC-43FC-84D4-4B45C3733F49 Q28586529-3BC34EF0-1B2F-4C30-8123-D8CC0C8EB166 Q28748511-33B5943B-1CF0-45B8-B249-649E7DAE2AD3 Q33633343-CB41027A-EE26-450C-BB1D-46DE8C3B672B Q33747751-84E59352-C864-44C7-BAC3-367DA61F3567 Q33751709-93406048-038A-45E2-A31A-F0773CE5A073 Q33792332-3568886E-3E9D-457E-B36B-E388A48D74FA Q33803185-0F49460B-528A-4E72-B8FF-B8FEBE7640DC Q33855961-2CBEA769-4827-4E15-B8EA-DDB8CEEA01B5 Q33982206-122C7B30-EA4A-41E9-8258-B0B9C5D890D3 Q34024241-0514EEFA-F50A-43FF-940D-076993948453 Q34057660-89984074-FB10-4622-868C-99FCBC3DF72A Q34331360-D4EF61C0-BB8B-4404-A2A2-A7628A3B892D Q34428446-E00EA446-DE7D-42EA-90A9-3F76D235B734 Q34465185-87D5B47B-299C-45F7-BBF8-9D6464505483 Q34477198-9FF02A03-97B1-476A-9749-56A4779F8E28 Q34516367-D84E7475-EC7D-4C35-B2C5-4A042989AFBA Q34516548-DEB1828A-5CAE-4233-809C-DD1A428EC7EF Q34554521-0B6A6D31-F90B-4291-9E53-96D82E75AF5B Q34613471-84C348F3-8BCB-4ED2-98CB-4835D9F25965 Q34692926-C07370F3-203F-422C-9898-FDBE730F98E8 Q34918287-48AEF82C-3D01-46A2-8E31-E4B4EC139CE7 Q35073767-2DF66FF6-C3D7-48FA-9DF8-9E56A8D5797A Q35100818-211DC183-DDC8-4DE4-A184-DEC5FE2B2DE7 Q35170385-7AB96482-A2E6-4366-AD59-804DF418F31A Q35171867-C30B1A35-FB5C-4E2D-8677-D53A60D79F6E Q35395169-F1482327-58A2-4030-82D1-09B42C9832C8 Q35396977-ACCF7014-18B0-4FB8-9160-81772087B712 Q35656939-E108A0D9-24EF-4464-B536-E1C6250E316A Q35664186-4C52F4C8-E056-4F59-9C95-A0C52C3BB409 Q35849300-DCDCD8A0-C6C6-4E3F-91D0-E40CA95E230E

P2860

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

Item

http://www.wikidata.org/entity/Q24600270

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu